Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3

Physiological Genomics

Volumn 16, Issue , 2004, Pages 334-340

  Griffin, J L ^a   Cemal, C K ^b   Pook, M A ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

Machado Joseph disease; Magic angle spinning; Metabolomics; Multivariate pattern recognition

Indexed keywords

4 AMINOBUTYRIC ACID; CHOLINE; GLUCOSE; GLUTAMINE; GLYCOGEN; LACTIC ACID; PHOSPHORYLCHOLINE; POLYGLUTAMINE; ATXN3 PROTEIN, HUMAN; MJD PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR;

AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN METABOLISM; CELL NUCLEUS INCLUSION BODY; CEREBELLUM; CONTROLLED STUDY; DISEASE COURSE; GLYCOLYSIS; HUMAN; MACHADO JOSEPH DISEASE; MOUSE; NONHUMAN; PATHOLOGY; PATTERN RECOGNITION; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPINOCEREBELLAR DEGENERATION; TRANSGENIC MOUSE; TRINUCLEOTIDE REPEAT; YEAST ARTIFICIAL CHROMOSOME; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TELENCEPHALON;

ANIMALIA; MUS MUSCULUS;

ANIMALS; BRAIN; CEREBELLUM; CHOLINE; DISEASE MODELS, ANIMAL; GAMMA-AMINOBUTYRIC ACID; GLUCOSE; GLUTAMINE; GLYCOGEN; HUMANS; LACTIC ACID; MACHADO-JOSEPH DISEASE; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PHENOTYPE; PHOSPHORYLCHOLINE; REPRESSOR PROTEINS; TELENCEPHALON; TRANSCRIPTION FACTORS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 1842430173     PISSN: 15312267     EISSN: None     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00149.2003     Document Type: Article

References (34)

1. Anthony ML, Sweatman BC, Beddell CR, Lindon JC, and Nicholson JK. Pattern recognition classification of the site of nephrotoxicity based on metabolic data derived from proton nuclear magnetic resonance spectra of urine. Mol Pharmacol 46: 199-211, 1994.
2. Berl S and Clarke DD. Metabolic compartmentation of glutamate. In: CNS Handbook of Neurochemistry, Chemical and Cellular Architecture. New York: Plenum, 1969, p. 447-472.
3. Birken DL and Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies on brain. Neurosci Biohav Rev 13: 23-31, 1989.
4. Brand A, Richter-Landsberg C, and Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15: 289-298, 1993.
5. Boesch SM, Schocke M, Burk K, Hollosi P, Fornai F, Aichner FT, Poewe W, and Felber S. Proton magnetic resonance spectroscopic imagining reveals differences in spinocerebellar ataxia types 2 and 6. J Magn Reson Imaging 13: 553-559, 2001.
6. Cemal CK, Carroll CJ, Lawrence L, Lowrie MB, Ruddle P, Al-Mahdawi S, King RH, Pook MA, Huxley C, and Chamberlain S. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet 11: 1075-1094, 2002.
7. Chai Y, Koppenhafer SL, Shoesmith SJ, Perez MK, and Paulson HL. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet 8: 673-82, 1999.
8. van Dellen A, Welch J, Dixon RM, Cordery P, York D, Styles P, Blakemore C, and Hannan AJ. N-acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport 11: 3751-3757, 2000.
9. Durr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, Chneiweiss H, Benomar A, Lyon-Caen O, Julien J, Serdaru M, Penet C, Agid Y, and Brice A. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 39: 490-499, 1996.
10. Eriksson L, Johansson E, Kettaneh-Wold N, and Wold S. Introduction to Multi- and Megavariate Data Analysis using Projection Methods (PCA and PLS). Umea, Sweden: Umetrics, 1999.
11. Evert BO, Wullner U, and Klockgether T. Cell death in polyglutamine diseases. Cell Tissue Res 301: 189-204, 2000.
12. Fujigasaki H, Uchihara T, Koyano S, Iwabuchi K, Yagishita S, Makifuchi T, Nakamura A, Ishida K, Toru S, Hirai S, Ishikawa K, Tanabe T, and Mizusawa H. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains. Exp Neurol 165: 248-256, 2000.
13. Gavaghan CL, Holmes E, Lenz E, Wilson ID, and Nicholson JK. An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse. FEBS Lett 484: 169-174, 2000.
14. Griffin JL, Williams HJ, Sang E, Clarke K, Rae C, and Nicholson JK. Metabolic profiling of genetic disorders: a multitissue (1)H nuclear magnetic resonance spectroscopic and pattern recognition study into dystrophic tissue. Anal Biochem 293: 16-21, 2001.
15. Griffin JL, Muller D, Woograsingh R, Jowatt V, Hindmarsh A, Nicholson JK, and Martin JE. Vitamin E deficiency and metabolic deficits in neuronal ceroid lipofuscinosis described by bioinformatics. Physiol Genomics 11: 195-203, 2002. First published October 15, 2002; 10.1152/physiolgenomics.00100.2002.
16. Griffin JL, Bollard M, Nicholson JK, and Bhakoo K. Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1)H-NMR spectroscopy. NMR Biomed 15: 375-384, 2002.
17. Hannan AJ. Trinucleotide-repeat expansions and neurodegenerative disease: a mechanism of pathogenesis. Clin Exp Pharmacol Physiol 23: 1015-1020, 1996.
18. Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, and Kakizuka A. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet 13: 196-202, 1996.
19. Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, and Beal MF. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 74: 2108-2119, 2000.
20. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I, Kimura J, Narumiya S, and Kakizuka A. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 8: 221-228, 1994.
21. Lodi R, Cooper JM, Bradley JL, Manners D, Styles P, Taylor DJ, and Schapia AH. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci USA 96: 10948-10949, 1999.
22. Mader I, Karitzky J, Klose U, Seeger U, Sperfeld A, Naegele T, Schick F, Ludolph A, and Grodd W. Proton MRS in Kennedy disease: absolute metabolite and macromolecular concentrations. J Magn Reson Imaging 16: 160-167, 2002.
23. Mascalchi M, Cosottini M, Lolli F, Salvi F, Tessa C, Macucci M, Tosetti M, Plasmati R, Ferlini A, Tassinari CA, and Villari N. Proton MR spectroscopy of the cerebellum and pons in patients with degenerative ataxia. Radiology 223: 371-378, 2002.
24. Matsuishi T, Sakai T, Naito E, Nagamitsu S, Kuroda Y, Iwashita H, and Kato H. Elevated cerebrospinal fluid lactate/pyruvate ratio in Machado-Joseph disease. Acta Neurol Scand 93: 72-75, 1996.
25. Orru S, Ruoppolo M, Francese S, Vitagliano L, Marino G, and Esposito C. Identification of tissue transglutaminase-reactive lysine residues in glyceraldehydes-3-phosphate dehydrogenase. Protein Sci 11: 137-146, 2002.
26. Raamsdonk LM, Teusink B, Broadhurst D, Zhang N, Hayes A, Walsh MC, Berden JA, Brindle KM, Kell DB, Rowland JJ, Westerhoff HV, van Dam K, and Oliver SG. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol 19: 45-50, 2001.
27. Rosenberg RN. Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov Disord 7: 193-203, 1992.
28. Schmidt T, Landwehrmeyer GB, Schmitt I, Trottier Y, Auburger G, Laccone F, Klockgether T, Volpel M, Epplen JT, Schols L, and Riess O. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol 8: 669-679, 1998.
29. Soong B, Cheng C, Liu R, and Shan D. Machado-Joseph disease: clinical, molecular, and metabolic characterization in Chinese kindreds. Ann Neurol 41: 446-452, 1997.
30. Stenoien DL, Mielke M, and Mancini MA. Intranuclear ataxin1 inclusions contain both fast and slow exchanging components. Nat Cell Biol 4: 806-810, 2002.
31. Takiyama Y, Oyanagi S, Kawashima S, Sakamoto H, Saito K, Yoshida M, Tsuji S, Mizuno Y, and Nishizawa M. A clinical and pathologic study of a large Japanese family with Machado-Joseph disease tightly linked to the DNA markers on chromosome 14q. Neurology 44: 1302-1308, 1994.
32. Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, Karube Y, Shimazaki H, Soutome M, Endo K, Ohta S, Kagawa Y, Kanazawa I, Mizuno Y, Yoshida M, Yuasa T, Horikawa Y, Oyanagi K, Nagai H, Kondo T, Inuzuka T, Onodera O, and Tsuji S. The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet 4: 300-304, 1993.
33. Taylor-Robinson SD, Weeks RA, Bryant DJ, Sargentoni J, Marcus CD, Harding AE, and Brooks DJ. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 11: 167-173, 1996.
34. Yen TC, Tzen KY, Chen MC, Chou YH, Chen RS, Chen CJ, Wey SP, Ting G, and Lu CS. Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers. J Nucl Med 43: 153-159, 2002.